[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 4 (Autumn 2023) ::
Caspian J Intern Med 2023, 14(4): 618-627 Back to browse issues page
Efficacy of prokinetic agents in diabetic gastroparesis comparing symptomatology and scintigraphy – An open-label trial
Ravi Kant , Madhuri Pratti , Meenakshi Khapre , Poonam Yadav , Vandana Dhingra
All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India , drpoonam457@gmail.com
Abstract:   (1126 Views)
Background: It is pertinent to objectively assess the severity of diabetic gastroparesis and tailor treatment accordingly. The current study was planned to document gastroparesis by gastric emptying scintigraphy (GES) objectively and see the effect of medications and diet control on clinical and GES after four weeks.
Methods: A prospective, open-label randomized trial was conducted in the Department of Internal Medicine at a tertiary care teaching hospital over twelve months. Type 2 diabetic patients aged 18-65 years diagnosed with a case of delayed gastric emptying by gastric scintigraphy were included. All baseline GSCI was recorded, and then they were allotted to 3 groups – Group-1 (Levosulpiride 25mg once daily), group-2 (Cinitapride 1mg thrice daily), and Group-3 (Waitlisted control) by block randomization and followed-up weekly till four weeks. After four weeks duration, if not improved clinically, then Group-3 on diet and diabetic control only, were randomized into Levosulpiride 25mg once daily (Group 1), and Cinitapride 1mg Thrice daily (Group 2) for the next four weeks.
Results: Forty confirmed cases with diabetic gastroparesis documented by Gastroparesis Symptom Cardinal Index (GCSI) scoring and later by Scintigraphy (GES) were included in this study. However, there was no statistically significant difference between the Levosulpiride and Cinitapride groups when all symptoms were taken into account. Levosulpiride was significantly more effective than Cinitapride in improving individual symptoms like nausea, vomiting, stomach fullness, and early satiety.
Conclusion: Levosulpiride is better than Cinitapride in improving the symptoms of diabetic gastroparesis but no significant effect on gastric scintigraphy.

Keywords: Cinitapride, Diabetes Mellitus, Gastroparesis, Gastric scintigraphy, Gastric Emptying, Levosulpiride.
Full-Text [PDF 823 kb]   (333 Downloads)    
Type of Study: Original Article | Subject: pharmacology
Received: 2021/05/26 | Accepted: 2022/07/24 | Published: 2023/09/19
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kant R, Pratti M, Khapre M, Yadav P, Dhingra V. Efficacy of prokinetic agents in diabetic gastroparesis comparing symptomatology and scintigraphy – An open-label trial. Caspian J Intern Med 2023; 14 (4) :618-627
URL: http://caspjim.com/article-1-2927-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 4 (Autumn 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 40 queries by YEKTAWEB 4652